MUNDIPHARMA
19.1.2021 09:02:43 CET | Business Wire | Press release
FOR MEDICAL BUSINESS/INDUSTRY TRADE MEDIA ONLY
The Mundipharma network of independently associated companies today announced two new appointments to their Executive Committee – Julie Dehaene-Puype as Chief Commercial Officer, Europe and Erik Nordkamp as Chief Commercial Officer, LAM (Latin America, Asia Pacific, Middle East-Africa) – both reporting into Marc Princen, Chief Executive Officer.
Speaking of the appointments, Marc Princen commented, “I am delighted to welcome Julie and Erik as highly experienced pharmaceutical leaders to complete our global organisation. They join us during a pivotal year for some of our pipeline assets as we continue to increase access to healthcare for many of the world’s most challenging diseases.”
Julie Dehaene-Puype is joining Mundipharma with over 20 years’ industry experience from Takeda, Merck and Schering Plough, where she has held strategic and operational roles at country, regional and global level across the US, Europe and Canada. Julie joins Mundipharma from Takeda where she was recently General Manager of France. Her role at Mundipharma will see her cover the Europe region.
“I am thrilled to be joining the Mundipharma global organisation,” Julie commented. “I am looking forward to utilising my experience to build on the inclusive culture that enables our people to work together, think differently and to transform the lives of patients all around the world.”
Erik Nordkamp is a pharmaceutical professional with over 20 years’ experience in strategy, general management and marketing from Pfizer and Eli Lilly, with regional roles that have spanned Europe, Canada and Australia. Most recently Erik was Regional VP & Cluster Lead Europe/Australia/NZ Upjohn Division at Pfizer. His new role at Mundipharma will see him cover the LAM region, which encompasses Latin America, Asia Pacific, Middle East-Africa.
Commenting on his appointment, Erik said: “This is an exciting time for Mundipharma as we expand our global network and I feel proud to be taking responsibility for the key LAM region. Think global, act local is how I envision we can deliver lasting change for patients.”
-Ends-
Notes to editors:
About the Mundipharma network
Mundipharma is a global (ex-US) network of independent associated companies with a presence across Africa, Asia Pacific, Canada, Europe, Latin America and the Middle East.
As a dynamic, forward-looking organisation we are dedicated to bringing innovative treatments to patients in the areas of Pain & Supportive Care and Consumer Healthcare as well as other severe and debilitating disease areas.
Our guiding principles, centred around Integrity and Patient-Centricity, are at the heart of everything we do.
For more information visit www.mundipharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005163/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 09:00:00 CEST | Press release
New One-Day Intensive Experience Offered 9 June Ahead of Conference 10-11 June at Tobacco Dock Featuring 10 Stages and 14 Tracks The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights
Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 08:00:00 CEST | Press release
From dating apps to financial details, respondents report seeing a wide range of highly personal information on others' screens 56% of people admit to having looked at strangers’ phone screens accidentally, whereas 24% have done so out of curiosity. 57% identify public transport as the most likely place to notice someone else's screen. While 48%* feel confident they can keep their phone activity private when using it in crowded places, another 52%** acknowledge it is easy to see someone’s screen who is next to you in a public place without trying to look. 33% say they have seen personal content on a stranger’s phone in public. Some smartphone users who have looked at a stranger’s phone screen in public ignore and continue what they were doing (28%) or look away immediately (27%), but others (7%) admit to continuing to look discreetly. The new Samsung Galaxy S26 Privacy Display1 limits side-angle viewing of your screen to protect your privacy in any setting. As millions of Europeans2 ge
RevolKa Reimagines Antibody Engineering with "RevoAb®"1.4.2026 06:30:00 CEST | Press release
A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa’s advanced AI Protein Engineering Engine RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allo
Global Beauty Market Grows 10% as AI and E-commerce Reshape Consumer Buying1.4.2026 03:00:00 CEST | Press release
Online sales outpace in-store by 6x as digital-first and AI-influenced commerce accelerates globally NielsenIQ (NYSE:NIQ), a global leader in consumer intelligence, today released its State of Beauty 2026 report, showing the global beauty market grew 10% year-on-year, with E-commerce expanding six times faster than in-store sales. The findings highlight a rapid shift to digital-first, AI-influenced commerce across key global markets. As consumer expectations evolve toward convenience, personalization, and seamless digital experiences, beauty brands are under increasing pressure to adapt. From AI-powered product discovery to social commerce and livestream shopping, the path to purchase is becoming more dynamic—requiring brands to move faster and engage consumers across an increasingly complex ecosystem. Key findings from the State of Beauty 2026 report: Global beauty sales grew 10% year-over-year, driven by strong digital acceleration E-commerce is growing 6x faster than in-store sales,
bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering31.3.2026 19:01:00 CEST | Press release
Streamlines Hillside Technology testing across browsers and mobile devices while supporting rapid expansion into regulated markets. TestMu AI (Formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced that Hillside Technology Limited, the technology powerhouse behind global online gambling leader bet365, has adopted its platform to unify software testing and support hundreds of weekly production releases. The global online gaming industry is currently experiencing a massive shift, with the market projected to exceed $150 billion by 2030. As mobile gaming becomes the primary touchpoint for users, the technical complexity of delivering a seamless, low-latency experience has grown exponentially. For industry giants like bet365, the need to validate software across an infinite matrix of hardware, screen resolutions, and OS versions is a mission-critical requirement. This partnership ensures that, as gaming becomes more mobile-centric, bet36
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom